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ABSTRACT 
 
Liposomes though successful in achieving targeted drug delivery and sustain release 
limitations like short circulating rates due to MPS uptake and many factors prove that 
there is need to modify the characteristics of the liposome in size, permeability and 
hydrophilicity. One of such modifications is done and characterized in this report. Surface 
modification of liposomes was done by using a polymer CMC (Carboxy methyl chitosan) 
in different proportions to preformed liposomes. Initially liposomes were prepared 
through sonication method and CMC solution was added in specific concentrations along 
with glutaraldehyde as cross linking agent. Physical Characterization of surface modified 
liposomes done by microscopic studies, stability studies at different temperatures such as 
37°C, 4°C and -20°C. Particle size distribution and Zeta potential of normal and surface 
modified liposomes was analyzed using DLS. Biological characterization by protein 
loading and release studies. Haemocompatibility was checked using goat blood as it 
ensures the use of liposomes in Invitro studies. Invitro studies using 5-Fluoro uracil. 
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INTRODUCTION: 
Recent years have many revolutionaries in using nanoparticles as drug delivery carriers due 
to so a many undesired effects and limitations in direct drug uptake. One of them was 
liposomal drug delivery. Liposomes are artificial vesicles comprises o f one or more bi layers 
enclosing an aqueous phase. Initially the use of liposomes confined only to model 
membranes. But recently they are being used from a carrier for drug delivery to desired 
cellular and sub cellular sites along as vehicles for the transfer of genetic and other materials 
to the cell. (Berg and Bonam et al., 1973). Conventional liposomes being rapidly cleared 
from the circulation by MPS system of the body. To avoid this surface modification with 
positive and negative charge lipids and incorporating respective polymers and many other 
Biomolecules dramatically increased the circulation of liposomes to circulate for longer 
periods than that of un modified lipid carriers. This made a way to use the liposomes as drug 
delivery carriers in many cases in which sustain release is required e.g. (antimalarial drug 
chloroquine or the radical scavenger superoxide dismutase), and resulted in greatly reducing 
the side effects of the drugs (side effects of doxorubicin towards smooth muscle of heart), 
lowering the hemolytic effect there by imparting protection against local irritation of 
intradermal or sub cutaneous injection in case of tissue irritating drugs. Surface modification 
there by proved striking improvements in the therapeutic potential of liposomes. So one of 
the modifications was implemented and characterized physically and biologically. 
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REVIEW OF LITERATURE: 
Liposomes as nanoparticles for drug delivery: 
Liposomes are spherical closed vesicles made up of phospholipids like phosphotidyl choline 
and cholesterol bilayer encapsulates a part of the solvent, in which they can freely enclosed 
into their interior parts of the vesicles .Vesicles comprising lipid bilayer encapsulating the 
aqueous core components occurs in either small or large unilamellar type vesicles, while in 
the presence of many concentric bilayers they are called large multilamellar vesicles 
(L.M.V). (A. D. Bangham et al., 1978) 
Physical parameters like structure, vesicle shape, chemical composition and colloidal size can 
be well controlled during the preparation of liposomes. Due to many unique properties of 
liposomes the scope of using them as therapeutic carriers was very promising. Their colloidal 
size, permeability of the membrane and surface characteristics play an important role in their 
application. Generally they range from 20nm-10µm. These include phase behavior of the 
bilayer, corresponding mechanical properties, charge, density, permeability due to the 
presence of surface bound or grafted polymers or attachment of corresponding ligands. (A.S. 
Ulrich et al., 2002) primarily due to their amphiphilic nature, liposomes are very much able to 
make a very appropriate solvent system for a wide range of components. Along with these 
unique physico-chemical properties, liposomal carriers exhibit many special biological 
characteristics including specific interactions with biological membranes and various cells 
through receptors mediation or diffusion. 
• Preparation of Liposomes 
There is a systemic process or characteristic on which the method of preparation of liposomes 
basically depends on. Depending on the strategy of preparation the preparing methodology can be 
broadly classified in to mainly three groups:-
      I. Mechanical methods 
 A) Film method. 
Although many procedures came in due course of time out of all the simplest of all the 
procedures is the original method proposed by Bangham et al in 1979. Throughout the 
    

simplicity low encapsulation efficiency was the big limitation of this method. First of 
all in this method lipid films are formed by adding aqueous solvent literally hydration 
of lipid films by shaking at temperature above transition temperature which are 
deposited on the walls of rotary bottle and then the remaining organic solvent was 
removed by the help of rotary evaporator at reduced pressure rates.  After removing the 
trace amounts of organic solvent the resultant dried lipid layer was again hydrated by 
adding buffer generally phosphate buffer mostly water soluble this hydrating with 
buffer makes the lipid film to small closed vesicles, leaving only little amount of 
entrapped. The limitation of this method is that it yields heterogeneous sized population 
of liposomes. (Chu Chun – Jung et al., 1994). 
B) Ultrasonication method. 
Ultrasonication is one of the methods of producing liposomes. The lipid solutes are 
made to dissolve in organic solvents depending on the use and thoroughly dispersed to 
get a uniform distribution of lipids throughout the solvent. Then the lipid solution was 
added to drop by drop in the container maintained at 55°C prior adding lipid solution to 
it. Then it was sonicated for 15-20 minutes continuously to get a liposomal solution of 
heterogeneous populations. After to get homogenous and small liposomes the liposomal 
suspension was further sonicated using probe sonicator for 15 minutes at high voltage 
successfully yields small unilamellar vesicles (Oezden and Hasirci et al., 1991)
II. Reverse-phase evaporation Method. 
The method reverse phase evaporation deals with the preparation of liposomes. In this 
method the lipids are first dissolved to form a homogenous mixture of suspension of 
lipids required for liposome formation. Mainly phospholipids are used along with 
cholesterol and polymers may be added in case of special case. The whole system was 
then washed thoroughly with nitrogen and the lipids were redissolved in the organic 
phase. This is the point of phase at which the reverse phase vesicles will eventually form. 
Generally organic solvents like Chloroform, Diethyl ether and isopropyl ether or mixture 
are the usual solvents of choice used. Initially water in oil emulsion formed by brief 
sonication of a two phase system containing phospholipids in organic solvent and 
aqueous buffer. The organic solvent was removed under reduced pressure producing a 
viscous gel (Szoka and Papahadjopoulous et al., 1978). After the lipids were redissolved 
in the gel phase, the aqueous phase which containing compound to be encapsulated was 
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added to the flask. Then the whole system was interacted with nitrogen until it was 
thoroughly washed and then the sample was sonicated to get a mono phasic dispersion 
system. (Hand et al., 1987). Then the organic solvent from the mixture was removed to 
obtain a gel and it was also removed by the rotary evaporation.. The resulting liposomes 
are called reverse phase evaporation vesicles (REV) due to the name of the procedure. 
These unilamellar vesicles being large in size having the capacity to encapsulate large 
vesicles which are very large in size. The encapsulation efficiency of this method was 
relatively very high when compared to other methods. The major disadvantage or 
limitation of this method is the exposure of materials that are to be encapsulated to 
organic solvents and for a long period of sonication may lead to impairment of 
permeability which lead to defective loading efficiency. It has also been employed in 
entrapment of plasmids without damaging DNA strands. (Haga and Yogi et al.. 1989). 
     III. Freeze-thaw extrusion method. 
After the formation of liposomes through film method they were subjected to vortexing 
with the solute too be encapsulated so that entire formed lipid film form  Liposomes 
which are formed by the special film method are subjected to vortex along with the 
solvent used. This was done until complete solute was entrapped. The resulted film was 
kept from undissoved particles in the fluid. Then the vesicles produced are multi lamellar 
in nature. The liposomes formed were thus preserved  or frozen in acetone or dry ice bath. 
Then the frozen liposomes were then thawed using warm water and then subjected to 
vortexing again. The same process for repeated for many times and finally extruded. The 
liposomes thus formed by this specialized process are called large unilamellar vesicles by 
extrusion technique.  These liposomes contain internal solute concentration higher than 
the external solute concentration. This shows they have higher entrapment ratios. Proteins 
can be made effectively encapsulated by using this technique. (Pick, 1981; Ohaswa et al., 
1985; Yonethani and Liu, 1994). 
• Sizing of the Liposomes: 
After production of liposomes the sizing of the liposomes is important as it dictates the 
application of liposomes in every aspect therefore the liposomes production procedure must 
generate reproducible size distribution of a particle and the important parameter producing 
liposomes of certain range of size i.e., mostly using membranes of pore size of 0.2µm leads 
to the production of liposomes of size approximately 0.3µm to enhance the efficiency of 
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application in uniform which was very necessary. But in the heterogeneous population of 
liposomes primarily by separating by filtering through polycarbonate membranes at relatively 
low pressure rates, this allows sequential extrusion of particles depending on size; necessary 
care should be taken to seal the membrane holder tightly to avoid leakage.  This method was 
easy and reproducible. In this method there will be no chance of degradation of phospholipid 
and the encapsulation efficiency of liposomes can be made doubled.   (Hope M.J., Bally M. et 
al., 1985).  
The sizing of liposomes can also be done by gel chromatography. But usually it was used to 
remove unencapsulated components based on separation process. Another broadly used 
method was sonication which was extensively used in sizing of liposomes. Overall probe 
sonication far better than normal bath sonicator due to its many advantages in p producing 
very small liposomes of nanometre range of approximately 20nm. (C.L.Van Broekhoven et 
al., 2004) but along with these the problems associated with the sizing of liposomes are in 
case of peroxidation reactions removal of oxygen will be made difficult. In case of using 
probe sonicator the metal particles released due to friction may lead to contamination of the 
sample. 
• DISPERSION METHODS:- 
I. Mechanical Dispersion Methods: 
A) Preparation of liposomes using lipid film hydration 
Preparation of Lipid solution for Hydration: 
This is the most prominent and commonly used method for the preparation of MLV. 
For the preparation of liposomes from a mixed composition of lipids, the key thing 
is to get a clear solution of lipids. Therefore to get a homogeneous mixture the lipids 
are dissolved in organic solvents. Chloroform or Chloroform + methanol are 
basically used as solvents to prepare the lipid solutions. While preparing liposomes 
from mixed lipid composition, the lipids are prior made to dissolve in the organic 
solvent and mixed thoroughly to get a homogenous mixture of lipid solution with 
uniform concentration throughout according to the  original  method was proposed 
by Bangham et al. and is still the simplest and easiest procedure for our liposome 
preparation.  
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B) French Pressure Cell Method 
French pressure cell method was simple in mode of operation, easy in process and rapid 
in producing the samples and reproducible in every way. In this method there is no 
formation of multi lamellar vesicles since they are extruded at pressure range of 20,000 
psi and at a temperature of 4°C by introducing a small orifice. Above all this method 
offers many advantages over sonication method in handling of most unstable materials 
which will be difficult in using sonication but the liposomes produced by this method 
were larger than that of sonicated small unilamellar vesicles along with the difficulty in 
achieving the prescribed temperature and especially in working with very small 
volumes approximately 50ml. 
II. Solvent Dispersion Methods: 
A) Ether Injection Method 
In this method the lipid solution is dissolved in ether/methanol or diethyl ether. The 
lipids were mixed well to get a uniform solution. The prepared mixture carefully was 
injected in to the aqueous solution. The amphiphilic aqueous mixture was injected in to 
the lipid solution slowly, which was used for encapsulation. The process temperature 
should be maintained at 60°C throughout the methodology or can also be done at 
reduced pressures. After this the liposomes were prepared by removing the ether at 
vacuum conditions. But the limitations of this method was the production of liposomes 
was heterogeneous ranging from 70-190nano meter range the exposure of organic 
solvents to high temperatures must be abstract depending on the stability of the system. 
(Dhcamcr and Banigham, 1976; Scnehieren et al., 1978). 
B) Ethanol Injection Method 
The MLVs are then quickly formed when the lipid solution is rapidly interjected to a 
huge excess of buffer. Heterogeneous population is the limitation of this method (30-
110 nm). The liposomes thus formed are highly dilute and to get rid of all the ethanol is 
very difficult because it generates azeotrope with water and the probability of 
decreasing the activity of many reactive bio molecules found to be very difficult even 
in the presence of alcohol.. (Batzri A.R, Korn et al., 1973). 
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2. Surface modification of liposomes 
Drug delivery systems have extreme consideration to grasp the selective delivery and 
dissemination of drugs to the objective disease sites for safety and clout. Therefore, 
workability of various types of particulate systems likes as liposomes, emulsions, lipid 
microspheres, and polymeric nanoparticles have been described as trenchant drug delivery 
systems. The amnesty of liposomes has been scrutinized to appear through their capture by 
the reticuloendothelial system (RES) which uses liposomes that are circulating in the blood 
stream and relegate them from the blood (Y. Nishioka et al., 2001). To set free drug 
molecules enveloped in liposomes selectively to target site, the restraint recognition of 
liposomes by RES and the discipline of their pharmacokinetics are mandatory. Exclusively, it 
is to obviate arrest by the phagocytic cells in the liver and spleen for adjunct of liposome 
dissemination time in the blood. Moreover, several factors of liposomes, such as chain length, 
unsaturation of lipids, lipid configuration, size and zeta potential, affect the circulation time 
of liposomes. Surface alteration of liposome membranes with monosialoganglioside GM1 or 
polyethylene glycol (PEG), conjugated lipid (PEG-lipid) has been there to greatly enhance 
the time for ccirculation (D.B. Fenske et al., 2008). Depending on these describing, the 
surface coating approach has been strongly reviewed to flourish striking liposome-based drug 
delivery systems. PEG is well said as a highly hydrophilic polymer with very low toxicity 
and therefore, PEG and its sprouts started widely using to improve the stability and 
pharmacokinetics of drug carriers and parent drug. In liposomal drug rendition, PEG-lipid 
was mostly used for surface coating of liposomes to reach augmentation of their circulation 
time in the blood. This proficiency has already proved for PEGylated liposomes 
(D.V.Devine, K. Wong et al., 1998). Specifically, doxorubicin-loaded PEGylated liposomes 
which are named Doxil® plot high efficacy and low toxicity. Therefore, In more than 80 
countries for the treatment of cancer, these have been broadly used in clinical applications 
and are well accepted .These facts clearly manifest the prominence of PEG alteration 
techniques for the production of shrewd liposomal drug delivery systems. Physiological and 
physicochemical stabilities and pharmacokinetics of PEGylated liposomes are affected by 
both the average amount of PEG attached to the liposome surface and deviation of PEG 
amounts among PEGylated liposomes. Along with PEG many polymers like PLA, PLGA, 
CMC, Chitosan, Gd- diethylenetriaminepentaacetyl-phosphatidylethanolamine (GdTPA-PE) 
are present. Generally targeted drug delivery deals with the intravenous use of colloidal 
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carriers for the targeting of drugs to specific target cells and organs in the body. Along with 
the polymers proteins and lectins like Concanavalin A, also had been used to enhance the 
binding to plant protoplasts in order to target the lipid vesicles with lectin molecules. As this 
lectin was used to label the plasma membrane and for structural analysis of glycoproteins. 
(Lis and Sharon et al., 1984), (Scarborough et al., 1975), Conjugation with liposomes resulted 
in high binding specificity and imparting stability to the carriers which were very essential  
prerequisite for the development of long circulating and site specific drug delivery carrier 
system. (H. Bakowsky et al., 2008). Folatereceptor (FR) conjugated was another prominent 
modification as FR often over expressed in cancers mainly of epithelial origin. It has 
frequently been exploited for the specific delivery of folate-linked drugs into cancer cells, 
along with folate-derivatized proteins, chemotherapeutic agents, vectors used for 
genetherapy, immunogenic haptens, imaging agents, and finally liposomes have been 
efficiently delivered into cancer cells by receptor-mediated internalization (P. Garin chesa et 
al., 1993). Recently it was been shown that folate-targeted liposomes containing doxorubicin 
are more potent than non-targeted liposomes in treating FR-expressing murine leukemias 
(X.Q. Pan, X. Zheng et al., 2002). ]. As activated macrophages also express FR, it was 
demonstrated that the use of folic acid as a ligand for targeting of liposomes to ascitic tumor 
cells and tumor associated macrophages in vivo. It can be conjectured that elimination of 
both of these cell populations would be conducive to the treatment of ovarian malignancies. 
(David J. Waters et al., 2003). 
The carriers are bothered with applications relating discharge of the drug carrier systems to 
the liver, chiefly by rectitude of the noticeable predilection of circulating colloidal particles to 
cooperate with the covetous cells of the mononuclear phagocyte system (MPS) (N.D.Santos 
et al., 2007) If in case the other organs take apt uptake of particles by MPS macrophages then  
this will become be a major problem to be rolled down. The key inducement of the 
endorsement kinetics and bio distribution of colloidal particles are the Surface characterstics 
and size. For explanations of savory blood supply, peculiar vascular architecture and the 
profusion of MPS cells, the important part of implanted particles with a lesser size will close 
up in the liver and spleen macrophages (D.C.Drummoud et al., 1999) .Exaggerate 
perceptivity to and evolution of diseases. Further detailed studies involve proper arrangement 
of properties of particles such as size, charge of surface and surface hydrophobicity and 
hydrophilicity.  A dominant finding in the application of colloidal particles was the discovery 
that steric stabilization can enhance particle endurance in the biological ambiance. Steric 
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compensation can be negotiated by surface connection of several natural or synthetic 
polymers (A.Gabizon et al., 2003) either by adsorption, hydrophobic insertion, electrostatic 
binding or alternately by propagating by using covalent bonds, Non-ionic, water harmonious, 
flexible and well-hydrated polymers are to be given priority. Thus, the usage of hydrophilic 
coatings to reduce uptake of circulating colloidal particles by the MPS has evolved as a 
prominent modern advancement. 
Nanoparticle Surface Coating 
Approximate 
Particle size 
(nm) 
Invitro result References 
Liposomes 
Polystyrene 
Poly(methyl 
methacrylate) 
Polyethylene glycol (PEG), 
monosialoganglioside (GM,) 
Phosphatidylinositol(PI), 
sulphatides, dextran, pullulan 
Poloaxamer-184 
Poloxamine-908 
Poloxamer-184 
                 -188 
                 -338 
                 -407 
Poloxamine-Y04 
                  -908 
                  -1508 
Polysorbate-SO 
Polyxyethylene (23) lauryl ether 
(Brij 35) 
Hydroxylpropyl cellulose 
(Klucel F) 
60 
60 
130 
130 
130 
130 
130 
130 
130 
130 
130 
130 
MPS avoidance  
observed 
Not reported 
Not reported 
MPS avoidance 
observed 
MPS avoidance 
observed 
MPS avoidance 
observed 
MPS avoidance not 
observed 
MPS avoidance not 
observed 
MPS avoidance not 
observed 
MPS avoidance 
Woodle, M.C et al., 2002 
Jacobsen, L.O et al., 1987 
Muller R.H etal., 1992 
Torchillin, V.P et al., 1994 
Kreuter. J et al., 1990 
Troster S.D. et al., 1992 
Lasic D.Det al., 1993 
Tauber U et al., 1979 
Leu D Mnathey et al., 
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Poly(butyl- 2 cyan 
acrylate 
Poly(-malic acid-
co-benzyl malatel 
Poly(-hydroxy 
butyrete) 
Poly (lactic acid) 
Poly(lactic acid co 
glycolic acid) 
O/W emulsion 
Soybean (10%) 
Ethoxylated di(nonyl)phenol 
(Antarox DM 970) 
Poloxamer-338 
Poloxamine-908 
Poloxamer-188 and -407 
Various poloxamines (-304. -
504. -704, -904, -908. -1504) 
Poloxamer-338 and -407 
Poloxamine-908 
Ethoxylated nonylphenols 
(Antarox CO 970. Antarox CO 
990, Antarox DM 970, Gafac 
RE 960) 
Ethoxylated glycerols (SH EO 
75, SH EO 100 
Same as above 
PEG+ Same as above 
Poloxamine – 908  
as stabilizer (2%) 
130 
<200 
90-250 
90-250 
90-250 
90-250 
90-250 
90-250 
140 
250 
observed 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
Not reported 
MPS avoidance 
observed 
MPS avoidance 
observed 
1984 
Douglas S.J Daviset al., 
1986 
Stolnik S. Davis etal., 1994 
Muller R.H et al., 1994 
Walllis K.H et al., 1993 
Gref R. et al., 1994 
Illum L. West et al., 1989 
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• Limitations Of Liposomes As Drug Delivery Carriers:
Although there reminds a number of Biomolecules for alteration, limitations appears as 
follows: 
a) Rectified liposomes, encapsulated therapeutic agents are focused only on systematic 
administration. 
b) Few of them are unable to pass through the blood brain barrier.  
c) Not able to take a step up on multi drug resistance. 
d) Satisfactory results are not found in Pharmacokinetic and Preclinical studies. 
e) Toxicity may build up about a short span. 
f) No advancement in tolerability profile. 
• Rationale and objectives: 
The utilization of liposomes as a drug delivery carrier could be  insignificant if a new and 
advanced corrections are there to make stable lipid nanoparticles such that live up to its 
potential. Through an comprehensive literature review, it was said that CMC meets all the 
limitations due to its unique characteristics, mostly it was found that there happened dearth in 
model material for modification. Therefore CMC was taken as modification material. 
  
3. Significance of CMC in pharmaceutical applications: 
Chitosan occurred to be biodegradable polymer accessed by the deacetylating  chitin, which 
is found in shells of insects and marine crustacean (Kas, 1997; Roberts, 1992). This polymer 
is a marine based polymer. Chitosan consists a number of beneficial properties including 
biodegradability, bio compatibility, bioactivity, non-toxicity and also good adhesion and 
absorption.It acquire antimicrobial and wound-healing properties. Furthermore, chitosan 
displays a pseudo plastic and viscoelastic behaviour. The muco adhesive properties of 
chitosan are actuated by the establishment of either secondary chemical bonds like as 
hydrogen bonds and ionic interactions between the positively charged amino groups of 
chitosan and the negatively charged group. These properties are sole responsible to a wide 
range of applications (Ravi Kumar, et al., 2000). Chitosan is a valuable and prominent 
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component of polymer blends and composites (Mucha & Mis´kiewicz, 2000; Mucha, Wan 
kowicz, & Balcerzak, 2007). By taking use of an appropriate technological process, many 
types of carriers like films, fibers, gels, foams and beads can be discovered. Most in vitro 
studies have examined the response of muscle cells, macrophages, chondrocytes, osteoblasts, 
erythrocytes and whole blood to chitosan. Moreover, many studies have been induced with 
mice, rats, rabbits and canine animal models in order to check the compatibility in vivo 
biocompatibility, degree of biodegradability, drug delivery, delivery of genetic material like 
DNA and wound healing using chitosan as our drug delivery carrier. (Fukuda, 1980; Kato, 
Onishi, &Machida, 2003; Onsoyen & Skaugrud) Controlled delivery devices that use and 
utilize biodegradable polymers have a key advantage over the competing delivery systems. In 
that device there is no need for surgical removal of the device. Furthermore, if the polymer 
degrades at the surface, the drug release process is justified by water that is diffused into the 
bulk is minimized and drug release rate is governed by polymer degradation rate.  
4. 5-FluoroUracil mode of action as anticancer drug: 
5-fluorouracil is a well known chemotherapeutic drug which is a topoisomerase I inhibitor 
used worldly in the treatment of metastatic colorectal cancer, this can be used solely or it can 
be used in consolidation with irinotecan. 5-FU was regarded to perfectly an S phase mobile 
chemotherapeutic agent, which doesn’t have any activity when cells are appeared to be in  G0 
or G1 stages. It is greatly entrenched that treating cells with 5-FU leads to damage of DNA, 
litrally doublestrand gets break when in S phase due to the reason that misin corporation of 
FdUTP falls into DNA (Curtin NJ, Harris AL, Aherne GW et al., 1991). Despite, DNA  can 
be damaged when occuring in all cell cycle phases and in proliferating cells . The overhaul 
auspices introduced may vary in various phases of the cell cycle (Gottifredi V, Prives C: et 
al., 2005). DNA catastrophe checkpoints are occured in G1, S and G2 due to couple DNA 
damage, detection to restraint of cell cycle evolution, provocation of DNA repair, subsistence 
of gnomic stability and when the situation comes that repair can’t be done, on the whole 
drags to initiation of cellular senescence. When traditional methods are absurd, 5-FU can be 
brought in the situation for using treatment locations even though at very low concentrations. 
Fluorouracil taken in embodiment injection has been perceptible in the palliative 
management of few species of cancer in addition to oesophageal, pancreas, rectum, cervical, 
gastric, biliary tract, colon, rectum, stomach, neck, head, renal cell, carcinoid, and breast, The 
Pharmacodynamics of Fluorouracil is found to be anti neoplastic anti-metabolite in nature 
    

(Peters GJ, Backus HH, Freemantle S, van Triest B) . The role of Anti-metabolites is to 
facade as purine or pyrimidine which evolves in the formulating stones of DNA. These Anti-
metabolites prevent the substances from agreeable amalgamated into DNA during the 
synthetic, "S" phase of the cell cycle. Therefore preventing general progress and division. 
Moreover Fluorouracil obstructs an enzyme which is responsible for changing the cytosine 
nucleotide to deoxy derivative. 5’FU inserted due to the reason that Fluorouracil obstruct the 
embodiment of thymidine nucleotide into DNA strand (Johnston PG, Lenz HJ 2005). The 
precise and clear mechanism  of 5-FU has not been completely discovered, but the pivot 
mechanism of fluorouracil is observed to be the irreversible bonding of the deoxy ribo 
nucleotide of pyrimidine. The location of tumour cells in the cycle of cell and it’s capability 
to go through apoptosis in reaction to drug treatment plays a prominent role in the delicacy of 
tumour cells to chemotherapy. 5-FU has a complex contrivance of action with various 
enzymes included in its metabolic appliance (Boyer J, McLean EG, et al., 2004). It arrests 
thymidylate synthase as it is key contrivance of action which leads to the depletion of dTTP. 
High elucidation of thymidylate synthase was shown to be accomplice with 5-FU resistance 
in colorectal cancer (Peters GJ, Backus HH et al., 2002). Even then it is also attainable that 
other corrections, for example, to acute genes on cycle of cell and executive pathways, 
dispose the advancement of resistance.
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MATERIALS REQUIRED 
Materials:  Lecithin (HIMEDIA), Cholesterol (HIMEDIA), Sphingolipid(N-acetyl-D-
sphingosine),  Diethyl ether (MERCK), PBS (Phosphate buffer saline), CMC (Carboxy 
methyl chitosan), Glutaraldehyde, Glycine, 5- Bromo Uracil, 0.1NNaOH, 0.1NHCl, 
Coomassie brilliant blue G, Rhodamine, Floral yellow(fluorescent dye) 
METHODOLOGY 
Preparation of liposomes:  
 Liposomes were prepared by Ultra Sonication method. Lipid solution comprising 
(cholesterol: Soy Lecithin: 1:12 were prepared in diethyl ether and the solution was made up 
to 2ml in a conical tube. The temperature of bath sonicator set at 55
0
C and beaker containing 
PBS buffer of 40ml kept in the sonicator with the help of a thermo coal float. Thus prepared 
lipid solution then added periodically by using micropipette of the volume 20µl into the 
preheated (at 55
0
C) aqueous phase PBS (pH 7.4) in specific time intervals. The solution was 
allowed to sonicate for another 15min. 
Surface modification of Liposomes by using CMC 
The liposomal suspension was divided to four batches each containing 10ml in four different 
conical tubes. An aliquot of 1%w/v CMC was prepared, from that add 0.05%, 0.075%, 0.1% 
to three of the liposomal suspension leaving one as control (without CMC). A 20µl of 0.05% 
Glutaraldehyde was added to the samples for cross linking for 30min. After half an hour 1ml 
of 0.1M Glycine was added to the cross linked sample to quench the unreacted 
glutaraldehyde. 
The liposomal suspension was centrifuged at 4000rpm for 10min and the pellet resuspened in 
5ml of fresh PBS and 1ml of the sample was filtered through syringe filter of the pore size 
0.22µm to avoid larger liposomes.  
Physical Characterization of Liposomes: 
     (i) Visualization of liposomes using Microscope: 
        Liposomes were viewed using Leica DM750 microscope and were counted manually. 
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 (ii) Average size and Particle distribution: 
      The particle average size distribution was analysed by using DLS (Dynamic light 
scattering) also known as photon correlation spectroscopy or quasi-elastic light scattering is a 
technique in physics that can be used to determine the size distribution profile of 
small particles in suspensions or polymers in solution. 
 (iii) Zeta potential 
Zeta potential refers to the charge on the particle which determines the stability of the 
emulsion by maintaining the dispersion of the particles avoiding agglomeration. Filtered and 
non filtered samples of both plain and CMC modified liposomes were analysed. 
Stability Studies : 
  (i) Stability of liposomes at different temperatures through microscopic analysis:  
        Aqueous stability depends on the lipid oxidation due to exposure of time so the stability 
studies are taken different intervals of time in 24hrs with respect to temperature. From the 
readings taken from samples at room temperature, 4
0 
C and -20
0
C. The readings show that 
liposomal solutions were stable at 4
0
C rather than room temperature and in -20
0 
liposomes are 
least stable due to ice crystal formation which further leads to rupture of membrane. 
               From the above results it is shown that the maximum number of liposomes is found 
in 1:10 ratio of soy lecithin and cholesterol concentrations and they are more stable at 4
0 
C 
providing chance to store the liposomes so that they can be preserved and used for drug 
delivery purpose. 
     (ii) Stability of liposomes at different pH: 
Effect of pH on liposomes was estimated by separating the liposomal suspension into four 
samples. Control taken as uncentrifuged and to the remaining three samples PBS buffer, 
0.1NHCl, 0.1NNaOH was added. The initial O.D was taken at 600nm and corresponding O.D 
was taken at half an hour, 1hr, 1.5hr, and 2hr respectively. (Fig  
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Dye entrapment studies: 
Before loading drug in to liposomes the entrapment efficiency and release studies were done 
using dye which serves as preliminary studies. For this 1% dye solution using Coomassie 
brilliant blue and Rhodamine in PBS was prepared. Liposomes were prepared using that 
buffer solution. Dye entrapped liposomes were centrifuged using Remi Cooling Centrifuge 
for 10min at 4000rpm. Then pellet was taken carefully washed for 2-3 times using fresh PBS 
so that free dye whatever remained could be washed off. O.D was taken at respective 
nanometre range and entrapment efficiency and release were estimated using standard graphs 
of the dye 
Protein loading Studies  
BSA (Bovine serum albumin) was taken as model protein. A 1%, 0.5% and 0.25% protein 
solutions were made in PBS. Liposomes were prepared using protein solution and loading 
estimated by O.D at 595 nm using spectrophotometer. BSA standard curve can be taken as 
reference. 
Protein release studies 
Liposomes were loaded with protein and centrifuged at 4000rpm for 10min. Pellet 
resuspended in fresh PBS and the sample incubated at 37°C for 24 hrs. The amount of protein 
released was analysed by comparing the O.D at 595nm using BSA standard curve. 
Fluorescent spectroscopy 
A 0.1% dye solution was prepared by adding 10mg of floral yellow in lml of diethyl ether. 
100µl of dye solution dissolved in 39ml of PBS, further used for the preparation of 
liposomes. Samples were centrifuged and filtered through syringe filter of pore size 0.22µm. 
The resultant samples were characterizes using fluorescent spectroscope. (Fig: 4) 
Haemocompatibility Tests 
Any drug delivery carrier system should compatible with blood so that it can reach the target 
site with out any disintegration. CMC modified liposomes were prepared by sonication 
method. 8ml of goat blood was taken and 10ml of 0.9% saline was added to that. Positive and 
negative controls were made by adding 0.5ml of 0.01N Hcl and 0.5ml of PBS respectively. 
Sample was 0.5ml of liposomal solution added to 9ml of saline +0.5ml of diluted blood. The 
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samples were centrifuged along with positive and negative controls at 4000rpm for 10minutes 
to settle all the blood components. If any RBC are ruptured its contents will be released in to 
supernatant. Then O.D of supernatant was taken at 545nm. Percentage of haemolysis was 
calculated by using the formula. 
% Hemolysis = 100 X (OD545 of the free Hb) / (OD545 of the total Hb). 
Drug Encapsulation Studies 
This study was done using 5-Fluoro Uracil, an anti cancer drug. 40mg of drug was dissolved 
in 40ml of PBS and liposomes were prepared, surface modified using CMC and release 
studies were Invitro. 
INVITRO STUDIES 
Cell culture Protocol 
 Cell lines were taken and washed with 1-2ml of PBS to remove all the traces of serum 
which contains trypsin. 
 PBS was discarded carefully. 
 A 1-2ml of trypsin was added along with EDTA and made sure that they had reached 
entire area of substrate. 
 Incubated for 3-4min at 37°C for in order to detach cells from substrate. 
 Then 1ml of Minimal essential medium+ 10%FBS+1%Antibiotic was added to 
trypsinised cells. 
 The cell suspension was then transferred to a 50ml of conical tube and centrifuged for 
3-4min at 1000rpm. 
 Supernatant was discarded after centrifugation carefully using a pipette above the 
pellet. 
 A 1ml of fresh medium added to the conical flask and the pellet was resuspended. 
 Transferred 200 l of the cell suspension into a 1.5 ml centrifuge tube 
 A mixture of 300 l of PBS and 500 l of 0.4% trypan blue solution added to the cell 
suspension in the centrifuge tube 
 Mixed thoroughly and allowed to stand for 5 to 15 minutes. Here care should be taken 
because if cells are exposed to trypan blue for extended periods of time, viable cells 
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may begin to take up dye as well as non-viable cells, thus, cell counting have to be 
done  within one hour after dye solution is added. 
MTT Assay 
Though many protocols are available for determining the viability of cells, MTT assay easy 
to perform and the best calorimetric assay for measuring the activity of cellular enzymes. The 
principle of this assay is MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5- diphenyltetrazolium 
bromide, a tetrazole) is reduced to formazan which gives purple color in the mitochondria of 
living cells. The absorbance of this colored solution can be quantified by measuring at a 
certain wavelength usually between 500 and 600 nm by using a spectrophotometer. The 
absorption max is dependent on the solvent used. This reduction takes place only when 
mitochondrial reductase enzymes are active, and therefore conversion can be directly related 
to the number of viable cells. When the amount of purple formazan produced by cells treated 
with an agent is compared with the amount of formazan produced by untreated control cells, 
the effectiveness of the agent in causing death of cells can be deduced, through the 
production of a dose-response curve. 
In vitro toxicity study of 5-fluorouracil loaded CMC modified liposomes 
For the preparation of drug loaded giant liposomes, 1 gm of 5 flurouracil was taken in a 100 
ml PBS and mixed it by putting in stirrer for 15 to 20 minutes. Then liposome suspension 
was prepared. It was then centrifuged and resuspended in 5ml PBS and incubated for 24hr at 
37°C. The releseate containing the drug was filtered through a 0.22m filter. HeLa cells were 
cultured in MEM /10% FBS and seeded in a 96 well plate at a concentration of 1x105 
cells/ml. The 10 l of releasate was administered per well. The toxicity of the cells was 
studied for 24hr by using MTT assay method. 
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RESULTS 
Liposomes were prepared using bath sonicator and surface modified by using different 
concentrations of CMC along with cross linking agent .Higher concentration of CMC 
resulted in increased in the size of liposomes. Liposomes were centrifuged at different ‘G’ 
value and corresponding O.D was taken. The results were represented in figures 1 & 2 
       Figure: 1Experimental setup for preparation of liposomes by Sonication method 
Figure: 2 Microscopic slide showing CMC modified liposomes 
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Stability Studies at different temperatures and pH 
Physiological properties of liposomes depend on many factors like temperature. Usually 
liposomes have low permeability to the encapsulated molecules (unless the molecule is 
membrane permeable). The permeability of the membrane changes with temperature. One of 
the most important properties of the lipid bilayer is the relative fluidity and mobility of each 
individual lipid molecule in the bilayer. The mobility of the lipids change with the change in 
temperature. So, the permeability which greatly depends on the temperature should be 
maintained in such a way that the encapsulation efficiency and permeability along with 
integrity of the bilayer. By the microscopic studies, found the liposomes were found to be 
stable at 4°C after 48hrs also. (Figure: 3) 
Fig: 3 Representing graph showing formation of number of liposomes formed 
atdifferent ratios of lipids 
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Table: 1 Table showing DLS and Zeta Potential of Normal and CMC modified 
liposomes 
Sample 
name 
Z-Average(d.nm) Zeta 
potential 
Conductivity(mS/cm) Count 
rate(Kcps) 
Control 258.1 -32.5 17.2 382.1 
0.05% CMC 265.2 -23.5 16.7 276.4 
0.075% CMC 278.4 -22.3 16.5 221.0 
0.1% CMC 289.5 -23.5 15.2 363.6 
Table: 2 Table containing DLS and Zeta Potential of Filtered Normal and CMC 
modified liposomes 
Sample name Z-Average(d.nm) Zeta 
potential 
Conductivity(mS
/cm) 
Count 
rate(Kcps) 
Filtered plain liposomes 168.4 -22.6 10.2 188.2 
Filtered CMC modified 
Liposomes 
218.7 -16.7 12.6 615.0 
From the above data the concentration of CMC had effect in size distribution along with 
charge of the liposomes there by making them more applicable in drug delivery and sustain 
release as increasing their stability. 
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Selection of Liposomes of Definite size range by Centrifugation at different RPM 
The liposome suspensions were taken and subjected to centrifugation at different rpm 2000, 
3000, 4000, and 5000 respectively at specific time interval. Corresponding O.D values taken 
at each interval to find the turbidity of the samples. The values were tabulated below. From 
the results it was clear that the turbidity decreasing with respect to ‘g’ value there by 
producing finer particles. 
Sample Name RPM ( Revolutions per Minute) 
2000 3000 4000 5000 
Control 0.980 0.945 0.820 0.735 
0.05% CMC 1.298 1.020 0.855 0.730 
0.075% CMC 1.123 1.019 0.783 0.632 
0.01% CMC 1.120 1.010 0.573 0.506 
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Figure: 5 Graph showing O.D at different values at ‘g’ of different conc of CMC
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Dye entrapment and release studies 
Prior to drug loading liposomes were checked for their encapsulation efficiency with two 
dyes namely coomassie brilliant blue G. R, and Rhodamine. From the standard graphs 
entrapment and release was about 20%. 
Standard curve of Rhodamine 
Protein loading and release studies 
BSA as a model protein dissolved in aqueous medium and liposomes were prepared, the 
protein loaded liposomes were incubated for 48hrs at 37°C. The amount of protein released 
was determined O.D taken at 545nm. The release was about 62%. Likewise loading studies 
were done by disrupting the liposomes by centrifuging at10000rpmfor 10min and amount of 
encapsulation was calculating O.D against the standard curve of the protein. Protein loading 
was about 25%. 
	    

Haemocompatibility study:  
An important measure of Haemocompatibility is the hemolysis test, which measures the 
ability of a material or material extract to cause red blood cells to rupture. Hemolysis testing 
should be performed on all materials directly contacting the bloodstream, or any materials 
used to form a fluid conduit to the bloodstream. This study is necessary for any drug delivery 
carrier as this dictates the rate and efficiency of drug and useful in evaluating a variety of 
drug delivery carriers intended to contact blood or fluids entering the circulatory system. 
From the results it was concluded though there was minute increase in O.D of surface 
modified liposomes than that of normal liposomes, the percentage of haemolysis not so far 
potential, so they can be used in systemic circulation with out any reservation. 
Results from this study were tabulated as follows (Figure: 6) 
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Fig: 6 Hemolysis study: Table and Graph showing hemolysis (OD at 545nm) by control, 0.05, 
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Sample Name % of Hemolysis 
Control 0.13% 
0.055 CMC 0.14% 
0.075% CMC 2.26% 
0.1% CMC 5.45% 
	    

Study of Cytotoxicity of drug loaded liposomes: 
To study the cytotoxicity of drug loaded liposomes, the liposomes were added to the cell culture 
medium and incubated at 370C 5% CO2 for 24 hours. Control was cells cultured without addition 
of drug loaded liposomes. After 24 hours, MTT assay was done to measure the cell proliferation. 
From the result, drug loaded liposomes showed cytotoxicity index of 0.26 as control was taken as 
1 for PBS. From the results it was found that the cytotoxicity caused by of CMC modified 
liposomes was relatively low when compared to normal liposomes. So, can be used for drug 
delivery in case of sustained release. 
Sample Name Percentage of Cytotoxicity 
PBS (Control) 1 
Liposome 0.93 
Liposome + 5FU 0.63 
0.05% CMC  liposome + 5FU 0.5 
0.075% CMC liposome + 5FU 0.35 
0.1% CMC liposome + 5FU 0.45 
Table consists of Cytotoxicity index of liposomes made of different concentrations of CMC 
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Summary and Conclusion 
Surface modified liposomes with CMC were successfully prepared and characterized 
physically using microscope. Stability studies were done for liposomes of different lipid 
concentration at different temperatures found stable at 4°C and at different pH range and 
found that stable at neutral pH. Size distribution profile was analysed by DLS and Zeta 
potential of liposomes confers charge and size vary after surface modification with CMC 
there by imparting stability. Dye entrapment and release studies were done prior to drug 
loading in order to ensure the encapsulating capacity of liposomes and resulted encapsulation 
was satisfactory. Drug lading and release studies were good at low concentrations as it 
depends on the solubility range of the drug. Haemocompatibility was fairly good as it 
resulted in less extent of RBC disruption. Invitro cytotoxicity of CMC modified liposomes 
was considerably low compared to normal liposomes there by proving that the surface 
modification leads to sustain drug release and Carboxy methyl chitosan may further be 
explored for its application in drug delivery of many other anti cancer drugs. 
Future Perspective 
• Modification of liposomes with acceptable polymers or other materials which will 
enhance the stability there by achieving targeted drug delivery without a hindrance. 
• Receptor mediated drug delivery can be made possible by tagging specific receptors 
to the cells of interest. 
• Different biomolecule targeting option may change the distribution of the drug along 
with target for delivery. 
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